Custom MHC Class II HLA-DP Xynapse and Dextramer R

The contract solicits the development of custom MHC Class II HLA-DP Xynapse and Dextramer reagents specifically for validating liver cancer neoantigens, targeting advanced immunological tools to enhance precision in cancer research. These reagents are critical for detecting and characterizing T-cell responses against neoantigens presented by HLA-DP molecules, which are essential in understanding immune recognition in hepatocellular carcinoma and other liver malignancies. The work requires precise molecular design, synthesis, and validation of reagents capable of high-affinity binding and specificity, ensuring reliable detection of rare antigen-specific T cells in patient samples. The project demands expertise in immunogenetics, protein engineering, and functional immune assays to meet rigorous performance thresholds. The solicitation, issued by the National Institutes of Health under the Department of Health and Human Services, is managed from Bethesda, Maryland, with a submission deadline of July 22, 2026. The NAICS code 813920 indicates the scope aligns with scientific research and development services, and the contract is open to all eligible vendors without specific set-asides. Patricia Haun serves as the primary point of contact for inquiries, and responses must be submitted through the SAM.gov portal. Successful applicants will deliver validated, ready-to-use reagents with full characterization data to support ongoing liver cancer immunotherapy research initiatives funded by the NIH.